SEC Form 4 · accession 0001209191-18-002547
IMMUNE DESIGN CORP. · IMDZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sergey Yurasov
Officer — Sr. VP, Clinic. Devel. & CMO
Period of report
Jan 4, 2018
Accepted (ET)
Jan 5, 2018 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 4, 2018 | A | 22,000 | $0.00 | A | 28,000 | D | |
| Common Stock | Jan 4, 2018 | S | 675 | $4.1725 | D | 27,325 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $4.05 | Jan 4, 2018 | A | 110,000 | A | — | Jan 4, 2028 | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
- F2Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date.
- F3One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date.